WALVAX(SZ:300142)2022-12-06 07:26Group 1: Market Recovery and Product Sales - The company's vaccine sales have significantly recovered, with over 20 products now available [2] - The market for vaccine procurement has returned to previous levels, with some regions performing even better [3] Group 2: R&D Progress of Key Products - Key products in advanced registration include the 13-valent pneumococcal conjugate vaccine, HPV vaccine, trastuzumab, and infliximab biosimilars, all currently in Phase III clinical trials [3] - The 13-valent pneumococcal conjugate vaccine is undergoing sample testing and is expected to complete this year [3] - The HPV vaccine has completed the full three-dose vaccination and is in the process of clinical follow-up [3] Group 3: Production and Certification - The 23-valent pneumococcal vaccine has completed multiple production batches and is expected to contribute to half a year's performance soon [3] - The company is advancing WHO pre-certification for several products, which is crucial for large-scale exports [3] Group 4: Industrialization and Investment - The company has invested nearly 2 billion RMB in a high-standard, large-scale production base in Yuxi, capable of producing over 100 million doses annually [4] - The monoclonal antibody production workshop has achieved international advanced levels in expression [4] Group 5: Core Competitiveness - The company possesses a leading R&D technology platform with a rich pipeline of products and a seamless integration of industrialization and registration processes [4]